Causal associations of education, lifestyle behaviors, and cardiometabolic traits with epigenetic age acceleration: a Mendelian randomization study

Lijie Kong,[1,2]* Chaojie Ye,[1,2]* Yiying Wang,[1,2] Jie Zheng,[3] Shuangyuan Wang,[1,2] Hong Lin,[1,2] Zhiyun Zhao,[1,2] Mian Li,[1,2] Yu Xu,[1,2] Jieli Lu,[1,2] Yuhong Chen,[1,2] Min Xu,[1,2] Weiqing Wang,[1,2] Guang Ning,[1,2] Yufang Bi,[1,2] Tiange Wang[1,2]

*Lijie Kong and Chaojie Ye contributed equally as first authors.

Author Affiliations:

[1]Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

[2]Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

[3]MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom.

Correspondence:

Tiange Wang, MD, PhD. Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rujin 2nd

Road, Shanghai, China. E-mail: wtg@live.cn. Phone number: 86-021-64370045.

Abstract

Background: GrimAge acceleration (GrimAgeAccel) and PhenoAge acceleration (PhenoAgeAccel) are DNA methylation-based markers of accelerated biological aging, standing out in predicting mortality and age-related cardiometabolic morbidities. Whether and to what extent modifiable risk factors are likely to influence GrimAgeAccel and PhenoAgeAccel, if causally established, could shed light on contributors to aging process and intervention targets for preventing age-related diseases and improving healthy longevity.

Methods: We performed two-sample univariable and multivariable Mendelian randomization (MR) to investigate the causal associations of 18 common modifiable socioeconomic, lifestyle, and cardiometabolic factors with GrimAgeAccel and PhenoAgeAccel. We extracted independent genetic variants strongly associated with the 18 modifiable factors from the largest available genome-wide association studies (GWASs) of European ancestry, ensuring minimum sample overlap with the genetic variants for GrimAgeAccel and PhenoAgeAccel. Summary-level data for GrimAgeAccel and PhenoAgeAccel were derived from a GWAS of 34,710 European participants. We used the inverse-variance weighted method as the main analysis, and the weighted median, MR-Egger, and MR pleiotropy residual sum and outlier methods as sensitivity analyses.

Results: Eleven and eight factors were causally associated with GrimAgeAccel and PhenoAgeAccel, respectively. Smoking initiation was the strongest risk factor (β [SE]: 1.299 [0.107] years) for GrimAgeAccel, followed by higher alcohol intake, higher waist circumference, daytime napping, higher body fat percentage, higher BMI, higher C-reactive protein, higher triglycerides, childhood obesity, and type 2 diabetes; whereas education was the strongest protective factor (β [SE] per 1-SD

increase in years of schooling: -1.143 [0.121] years). Higher waist circumference (β [SE]: 0.850 [0.269] years) and education (β [SE]: -0.718 [0.151] years) were the leading causal risk and protective factors for PhenoAgeAccel, respectively. Sensitivity analyses strengthened the robustness of these causal associations, and the multivariable MR analyses demonstrated independent direct effects of the strongest risk and protective factors on GrimAgeAccel and PhenoAgeAccel, respectively.

Conclusion: Our findings provide novel quantitative evidence on modifiable causal risk factors for epigenetic aging, and hints at underlying contributors and intervention targets to the aging process.

Keywords: Epigenetic age acceleration; Education; Lifestyle behaviors; Cardiometabolic traits; Mendelian randomization.

Introduction

Aging involves the gradual accumulation of a decline in multiple biological functions over time, leading to increased risks of developing age-related diseases and mortality [1,2]. Although chronological aging is uniform and unchangeable, the rate of biological aging is variable and modifiable depending on individual genetics, environmental exposures, and health-related behaviors [3]. Of several potential types of biological age predictors (e.g., epigenetic clock, leukocyte telomere length, and transcriptomic predictors), the epigenetic clock that composed of DNA methylation at multiple cytosine-phosphate-guanine (CpG) sites is currently the best one, as it correlates well with age and predicts mortality across populations [4]. The epigenetic age acceleration is the difference between chronological age and epigenetic age, and represents accelerated biological aging [5]. The second-generation epigenetic age acceleration indicators, namely GrimAge acceleration (GrimAgeAccel) and PhenoAge acceleration (PhenoAgeAccel), have been evolved to incorporate aging-related traits, and stand out in terms of predicting mortality and age-related cardiometabolic morbidities [6-9].

Limited observational evidence has suggested that certain socioeconomic, lifestyle behaviors, and cardiometabolic traits may be related to GrimAgeAccel and PhenoAgeAccel [6,7,10,11]. Whether and to what extent modifiable risk factors influence GrimAgeAccel and PhenoAgeAccel, if causally established, could shed light on potential contributors to aging process and elucidate promising targets for preventing age-related diseases and improving healthy longevity. [12,13]. Thus far, such causal evidence is scarce.

To fill this knowledge gap, we applied Mendelian randomization (MR) to evaluate the causal associations of 18 common modifiable socioeconomic, lifestyle

and cardiometabolic factors with GrimAgeAccel and PhenoAgeAccel. The MR method uses genetic variants as instrumental variables (IVs) to infer causality among correlated traits. Since genetic variants are randomly allocated at conception, the MR study is less susceptible to confounding and reverse causality than conventional observational studies [14]. We conducted both univariable and multivariable MR analyses to discern if modifiable factors have independent direct causal effects on GrimAgeAccel and PhenoAgeAccel.

Methods

Study design

This MR study design is presented in **Figure 1**. We performed two-sample univariable and multivariable MR strictly following the STROBE-MR guidelines (**Supplementary Table 1**) [15]. To obtain unbiased estimates of the causal effects, the MR analysis should adhere to three fundamental assumptions [16]: first, the IVs are truly associated with the exposures; second, the IVs are independent of confounders of the relationship between exposures and outcomes (GrimAgeAccel and PhenoAgeAccel); third, the IVs influence the outcomes only through the exposures, but not any direct or indirect pathways. All data used in this MR study are publicly available. Ethical approval and informed consent had been obtained in all original studies.

Selection rationale and data sources of genetic instruments

We selected 18 common modifiable factors including educational attainment, lifestyle behaviors (smoking initiation, alcohol intake, coffee consumption, daytime napping, sleep duration, and moderate-to vigorous physical activity [MVPA]), and

cardiometabolic traits (body mass index [BMI], waist circumference, body fat percentage [BF%], childhood obesity, type 2 diabetes, low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, systolic blood pressure [SBP], diastolic blood pressure [DBP], and C-reactive protein [CRP]). Definitions of the 18 modifiable factors are shown in **Supplementary Table 2**.

We extracted genetic variants for each of the modifiable factors from the largest available genome-wide association studies (GWASs) of European ancestry [17-29], ensuring minimum sample overlap with the genetic variants for GrimAgeAccel and PhenoAgeAccel (**Table 1**). We included single nucleotide polymorphisms (SNPs) robustly associated with the 18 modifiable factors at the genome-wide significance ($P < 5\times10^{-8}$). To select independent genetic variants, a stringent condition (linkage disequilibrium threshold of $r2 < 0.01$) was set to minimize the influence of linkage disequilibrium which may bias the results of randomized allele allocation. Where SNPs for the exposures were not available in the GWAS summary statistics of GrimAgeAccel or PhenoAgeAccel, we used proxies of SNPs with $r2 > 0.8$ as substitutes, by using the LDproxy search on the online platform LDlink (https://ldlink.nci.nih.gov/) [30].

Data source for epigenetic age acceleration

The genetic associations with GrimAgeAccel and PhenoAgeAccel were extracted from a recent GWAS meta-analysis (summary statistics available at https://datashare.is.ed.ac.uk/handle/10283/3645), which included 34,710 European participants from 28 cohorts [31]. GrimAgeAccel and PhenoAgeAccel are two-generation epigenetic age acceleration indicators, expressing the biological aging rate in years, of which GrimAgeAccel is more strongly associated with mortality than

PhenoAgeAccel [11]. Detailed definitions of GrimAgeAccel and PhenoAgeAccel and data preparation in GWAS are shown in **Supplementary Table 2**.

Statistical analyses

In the main analysis, we used the inverse-variance weighted (IVW) method to determine MR causal estimates (β coefficients with standard errors [SEs]) for associations of each modifiable factor with GrimAgeAccel and PhenoAgeAccel. The IVW combined the Wald ratio estimates of every single SNP in the set of IVs into one causal estimate using the random-effects meta-analysis approach [32]. To evaluate the robustness of the IVW estimates under different assumptions and to detect possible pleiotropy, we performed three sensitivity analyses, including the MR weighted median, the MR Egger, and the MR pleiotropy residual sum and outlier (MR-PRESSO) methods. The weighted median method selected the median MR estimate as the causal estimate, and provided a consistent causal estimate if over 50% of the weight in the analysis was derived from valid IVs [33]. The MR Egger method which allowed the intercept to be freely estimated as an indicator of pleiotropy was used to identify and adjust for the potential directional pleiotropic bias, but has limited precision [34]. The MR-PRESSO method was applied to detect and correct for any outlier SNP reflecting likely horizontal pleiotropic biases for MR causal estimates [35]. We evaluated the heterogeneity for the IVW estimates using the Cochran's Q test [36], and identified the horizontal pleiotropy based on the p-value for the intercept in the MR-Egger model [34]. A false discovery rate (FDR) method was used to correct results for multiple testing, and FDR q-values were provided. In this study, strong causal evidence was defined as an association supported by the main analysis (FDR q-value <0.05) and at least one sensitivity analysis. Suggestive causal evidence

was defined as a suggest association with P <0.05 and FDR q value ≥0.05 in the main analysis. Null causal evidence was defined as no statistically significant association revealed from the main analysis (P ≥0.05).

We further conducted multivariable MR (MVMR) analyses to assess whether the causal effects of the strongest protective factor and risk factor on GrimAgeAccel and PhenoAgeAccel were independent of other exposure factors [37]. Taking into account the effect size and significance of causal associations, we selected exposure factors with β coefficients >0.5 and P <0.05 in the main analysis as covariates in the adjustment models.

The two-sample MR analyses were conducted with the R packages '*TwoSampleMR'* and '*MRPRESSO*' in R software (version 4.0.3). FDR q-values were estimated using the R package '*fdrtool*'.

Results

MR results for associations between 18 modifiable factors and GrimAgeAccel

Ten out of the 18 risk factors showed strong associations with increased GrimAgeAccel after FDR adjustment for multiple comparisons (**Table 2**). Smoking initiation was the strongest risk factor (β [SE]: 1.299 [0.107] years) for GrimAgeAccel, followed by higher alcohol intake (β [SE] per 1-SD increase: 0.899 [0.361] years), higher waist circumference (β [SE] per 1-SD increase: 0.815 [0.184] years), daytime napping (β [SE]: 0.805 [0.355] years), higher BF% (β [SE] per 1-SD increase: 0.748 [0.120] years), higher BMI (β [SE] per 1-SD increase: 0.592 [0.079] years), higher CRP (β [SE] per 1-SD increase: 0.345 [0.073] years), higher triglycerides (β [SE] per 1-SD increase: 0.249 [0.091] years), childhood obesity (β [SE]: 0.200 [0.075] years), and type 2 diabetes (β [SE]: 0.095 [0.041] years; **Figure**

2). By contrast, educational attainment in years of schooling was the only one protective factor associated with decreased GrimAgeAccel (β [SE] per 1-SD increase: -1.143 [0.121] years). There was little evidence to support a causal association of other modifiable factors with GrimAgeAccel.

Associations of the above 11 modifiable factors with GrimAgeAccel were robust across sensitivity analyses with consistent effect directions and P <0.05 in at least one sensitivity analysis. The MR-Egger intercept tests indicated potential pleiotropy for CRP ($P_{intercept}$ <0.05; **Supplementary Table 3**). Cochran's Q-test showed possible heterogeneity for educational attainment, alcohol intake, BMI, BF%, type 2 diabetes, LDL cholesterol, HDL cholesterol, and CRP (P_h <0.05; **Supplementary Table 3**). However, with the exclusion of outlying SNPs, the MR-PRESSO analysis showed consistent results with the IVW analysis (**Table 2**).

MR results for associations between 18 modifiable factors and PhenoAgeAccel

Eight modifiable factors showed strong associations with PhenoAgeAccel after FDR adjustment for multiple comparisons (**Table 3**). Higher waist circumference was the strongest risk factor (β [SE] per 1-SD increase: 0.850 [0.269] years) for PhenoAgeAccel, followed by higher BF% (β [SE] per 1-SD increase: 0.711 [0.152] years), higher BMI (β [SE] per 1-SD increase: 0.586 [0.102] years), smoking initiation (β [SE]: 0.519 [0.142] years), higher CRP (β [SE] per 1-SD increase: 0.349 [0.095] years), childhood obesity (β [SE]: 0.229 [0.095] years), and type 2 diabetes (β [SE]: 0.125 [0.051] years). Whereas the genetically predicted higher educational attainment in years of schooling was associated with decreased PhenoAgeAccel (β [SE] per 1-SD increase: -0.718 [0.151] years; **Figure 3**). Suggestive causality was identified for the association between genetically predicted higher DBP and increased

PhenoAgeAccel (β [SE] per 1-mmHg increase: 0.049 [0.024] years). No significant association was observed with PhenoAgeAccel for the other modifiable factors.

Associations for the above eight modifiable factors were robust in sensitivity analyses with consistent effect directions and P <0.05 in at least one sensitivity analysis. There was no evidence of pleiotropy for these risk factors except for CRP ($P_{intercept}$ <0.05; **Supplementary Table 4**). Potential heterogeneity was observed for educational attainment, smoking initiation, BMI, waist circumference, BF%, type 2 diabetes, and CRP (P_h<0.05). One to four outliers were detected in the MR-PRESSO analyses; however, the associations remained consistent after removal of these outliers (**Table 3**). For SBP, with excluding the outlying SNP rs62523863, the MR-PRESSO analysis revealed a potentially positive association between genetically predicted higher SBP and PhenoAgeAccel (β [SE] per 1-mmHg increase: 0.038 [0.016] years).

MVMR results for associations of the strongest protective and risk factors with GrimAgeAccel and PhenoAgeAccel

In MVMR analyses, the association between educational attainment (the strongest protective factor) and GrimAgeAccel was slightly attenuated but remained significant with adjustment for smoking initiation, BMI, waist circumference, or BF% (**Figure 4a**). Likewise, the significant association between smoking initiation (the strongest risk factor) and GrimAgeAccel was not substantially changed after adjustment for BMI, waist circumference, or BF%. All covariates in MVMR analyses were selected based on their considerable effects on GrimAgeAccel in terms of size (β coefficients >0.5) and significance (P <0.05 in the main analysis).

Similarly, the associations of education (the strongest protective factor) and waist circumference (the strongest risk factor) with PhenoAgeAccel remained significant with adjustment for corresponding covariates (**Figure 4b**).

Discussion

This MR study delineated potential causal relationships between 18 common modifiable factors and two robust epigenetic age acceleration indicators, the GrimAgeAccel and PhenoAgeAccel. We identified strong evidence for 11 and eight factors associated with GrimAgeAccel and PhenoAgeAccel, respectively. Smoking initiation exhibited the greatest effect on increased GrimAgeAccel (1.299 years), followed by higher alcohol intake, higher waist circumference, daytime napping, higher BF%, higher BMI, higher CRP, higher triglycerides, childhood obesity, and type 2 diabetes; whereas educational attainment showed the greatest effect on decreased GrimAgeAccel (-1.143 years per 1-SD increase in years of schooling). Higher waist circumference and educational attainment were the leading causal risk and protective factors associated with PhenoAgeAccel, respectively; BF%, BMI, smoking initiation, CRP, childhood obesity, and type 2 diabetes were also associated with increased PhenoAgeAccel. Multiple sensitivity analyses further strengthened the robustness of these causal relationships, and the MVMR analyses demonstrated the independent direct effects of the strongest risk and protective factors on GrimAgeAccel and PhenoAgeAccel. Suggestive causality was identified for the association between higher DBP and increased PhenoAgeAccel.

In this study, educational attainment was the major protective factor for both GrimAgeAccel and PhenoAgeAccel, and this causal effect was largely independent of other causal factors, such as smoking and adiposity-related traits. Educational

attainment is a strong proxy for socioeconomic status and a more upstream determinant of health, with broad implications for a person's life-long lifestyle behaviors and health-promoting resources [38]. A recent study using UK Biobank data has documented that each 1-year increase in genetically determined educational attainment was associated with equivalently 4.2 years of age-related increases in telomere length [39]. Telomere length and epigenetic age acceleration metrics (e.g., GrimAgeAccel and PhenoAgeAccel) point towards distinct mechanisms of the aging process that are marked by telomeres and the DNA methylation-based epigenetic clocks, both of which are independently associated with chronological age and mortality risk [40]. Our findings, together with those of the UK Biobank, highlight the important impact of educational attainment on biological aging rates from two different aspects of the aging process. Therefore, public health strategies aimed at reducing educational inequalities and improving educational attainment may slow the biological aging rate and help reduce age-related health burdens.

This MR study identified several common lifestyle behaviors, including smoking initiation, alcohol intake, and daytime napping, causally associated with increased GrimAgeAccel or PhenoAgeAccel (smoking initiation only), which were consistent with previous evidence from observational studies [6,7]. Smoking methylation proxy is a component of the GrimAge clock [7], thus it is not surprising that smoking initiation exhibited a large effect on increased GrimAgeAccel, and the MVMR analysis further confirmed that the effect of smoking on GrimAgeAccel was independent of adiposity-related traits. Similarly, genetically determined smoking has been associated with shorter telomere length in the UK Biobank [41], and evidence from the Danish Health Interview Survey suggested that the life expectancy of a heavy smoker was a little more than seven years shorter than that of a never smoker

[42]. Our study also provided strong MR evidence that genetically predicted higher alcohol intake was associated with increased GrimAgeAccel. A study composed of the Hannum cohort and Family and Community Health Studies cohort found that the relationship between alcohol use and the first-generation epigenetic clocks seemed to be nonlinear [42]. However, given the dose-dependent relationship of alcohol intake with all-cause mortality and cancers [43], our findings suggest that reducing alcohol intake is necessary to decrease GrimAgeAccel and retard the overall health loss. Previous observational studies also reported positive or negative correlations of other lifestyle behaviors such as MVPA, coffee, and sleep duration with GrimAgeAccel, PhenoAgeAccel, or mortality [11,44,45]. Nevertheless, in this study, there was little evidence supporting these associations were causal. The discrepancy between our findings and previous observations may result from bias from confounding or reverse causation or non-linear association patterns, as in the case of sleep duration and mortality [46], therefore, our null findings should be cautiously interpreted.

Interestingly, of all cardiometabolic traits (i.e., adiposity traits, type 2 diabetes, triglycerides, and CRP) which causally increased GrimAgeAccel or PhenoAgeAccel, adiposity traits were the most dominant traits. Emerging observational studies have pronounced the positive associations of BMI with GrimAgeAccel and PhenoAgeAccel [11], and a meta-analysis of 87 observational studies showed each 5-kg/m^2 higher BMI corresponded to about 1 year of age-related decrease in telomere length [46]. Our study further provided strong evidence for causal associations of various adiposity phenotypes, including BMI, waist circumference, BF%, and childhood obesity, with increased GrimAgeAccel and PhenoAgeAccel. In this study, type 2 diabetes, triglycerides, and CRP showed strong but modest effects (β

coefficients ≤0.5) on GrimAgeAccel or PhenoAgeAccel, which was consistent with the findings of the UK Biobank study on telomere length [39].

Our study identifies education, lifestyle behaviors, and cardiometabolic traits associated with accelerating or decelerating epigenetic aging, which brings us one step closer to understanding the potential contributors to the aging process and provides promising intervention targets for healthy aging. Given the enormous burden induced by age-related morbidity and mortality, strategies to reduce educational inequalities, promote healthy lifestyles primarily through reducing smoking, alcohol intake, and daytime napping, and improve cardiometabolic traits, specifically adiposity, type 2 diabetes, triglycerides, and CRP, to slow biological aging rate are imminent.

To our knowledge, this MR study for the first time showed causal associations of comprehensive modifiable risk factors with GrimAgeAccel and PhenoAgeAccel, the robust second-generation epigenetic age acceleration indicators. We included independent and genome-wide significant SNPs as instruments for each of the modifiable factors to ensure the first MR assumption was fulfilled. Moreover, we applied strict criteria strengthened by the FDR-corrected significance and the cross-validations by main and sensitivity analyses to draw robust causal conclusions.

Several limitations merited consideration. First, we found potential pleiotropy from the MR-Egger intercept test for CRP. However, we conducted MR-PRESSO analysis, and the association remained consistent after removal of outlying SNPs. Second, we could not rule out the possibility that the associations of certain modifiable risk factors such as alcohol intake and sleep duration with GrimAgeAccel or PhenoAgeAccel may be non-linear. Future studies with individual-level data are warranted to confirm the linear or non-linear relationships. Third, to ensure the

consistency of genetic background, this MR study was performed only in European-ancestry participants, thus the generalization of our results to other ethnic groups should be cautious.

Conclusions

This MR study provided novel quantitative evidence on the modifiable causal risk profile of 11 socioeconomic, lifestyle, and cardiometabolic factors for epigenetic age acceleration. Our findings shed light on the underlying contributors to the biological aging process and point toward potential intervention targets to slow the biological aging rate and promote healthy longevity.

List of abbreviations

BF%	Body fat percentage
BMI	Body mass index
CI	Confidence interval
CpG	Cytosine-phosphate-guanine
CRP	C-reactive protein
DBP	Diastolic blood pressure
FDR	False discovery rate
GrimAgeAccel	GrimAge acceleration
GWAS	Genome-wide association study
HDL	High-density lipoprotein
IV	Instrumental variable
IVW	Inverse variance weighted
LDL	Low-density lipoprotein
MVPA	Moderate-to vigorous physical activity
MR	Mendelian randomization
MVMR	Multivariable Mendelian randomization
PhenoAgeAccel	PhenoAge acceleration
PRESSO	Pleiotropy residual sum and outlier
SBP	Systolic blood pressure
SD	Standard deviation
SE	Standard errors
SNP	Single nucleotide polymorphism
WM	Weighted median

Conflict-of-interest statement

The authors declare that they have no competing interests

Ethics approval and consent to participate

This study is based on publicly available summarized data. Ethical approval and informed consent had been obtained in all original studies.

Availability of data and materials

The genetic association data of the 18 modifiable factors are available in Table 1. The GWAS summary statistics for GrimAgeAccel and PhenoAgeAccel are available at https://datashare.is.ed.ac.uk/handle/10283/3645. The analytical script of the MR analyses conducted in this study is available via the GitHub repository of the "TwoSampleMR" R package (https://github.com/MRCIEU/TwoSampleMR/).

Funding

This work was supported by the grants from the National Natural Science Foundation of China (82022011, 81970706, 81730023, 82088102, 81970728, 81941017), the Chinese Academy of Medical Sciences (2018PT32017, 2019PT330006), the "Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant Support" from Shanghai Jiao Tong University School of Medicine (20171901 Round 2), the Shanghai Shenkang Hospital Development Center (SHDC12019101, SHDC2020CR1001A, SHDC2020CR3064B), the Shanghai Jiao Tong University School of Medicine (DLY201801), and the Ruijin Hospital (2018CR002).

Authors' contributions

LK and TW contributed to the conception and design of the study. LK and CY contributed to statistical analysis. LK contributed to drafting of the manuscript. TW guaranteed this work and take responsibility for the integrity of the data. All authors contributed to acquisition or interpretation of data, critical revision of the manuscript for important intellectual content, and final approval of the version to be published.

Acknowledgements

We gratefully acknowledge the investigators and participants of all genome-wide association studies from which we used data.

383 **References**

384 1. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol.*

385 2012;**22(17):**R741-R52.

386 2. Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage

387 in the ageing process. *Nature*. 2021;**592(7856):**695-703.

388 3. Warner HR. Current status of efforts to measure and modulate the biological rate of

389 aging. *J Gerontol A Biol Sci Med Sci.* 2004;**59(7):**692-6.

390 4. Jylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. *EBioMedicine*.

391 2017;**21:**29-36.

392 5. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock

393 theory of ageing. *Nat Rev Genet.* 2018;**19(6):**371-84.

394 6. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An

395 epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY).*

396 2018;**10(4):**573-91.

397 7. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation

398 GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY).*

399 2019;**11(2):**303-27.

400 8. Wang C, Ni W, Yao Y, et al. DNA methylation-based biomarkers of age

401 acceleration and all-cause death, myocardial infarction, stroke, and cancer in two

402 cohorts: The NAS, and KORA F4. *EBioMedicine*. 2021;**63:**103151.

403 9. Li A, Koch Z, Ideker T. Epigenetic aging: Biological age prediction and informing

404 a mechanistic theory of aging [published online ahead of print, 2022 Jun 20]. J *Intern*

Med.

10. Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY).* 2017;**9(2):**419-46.

11. Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks MP. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. *Ageing Res Rev.* 2021;**69:**101348.

12. Sierra F, Caspi A, Fortinsky RH, Haynes L, Lithgow GJ, Moffitt TE, et al. Moving geroscience from the bench to clinical care and health policy. *J Am Geriatr Soc.* 2021;**69(9):**2455-63.

13. Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. *Nature.* 2019;**571(7764):**183-92.

14. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ.* 2018;**362:**k601.

15. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. *BMJ.* 2021;**375:**n2233.

16. Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent Developments in Mendelian Randomization Studies. *Curr Epidemiol Rep*. 2017;**4(4):**330-45.

17. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet*. 2018;**50(8):**1112-1121.

18. Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet*. 2019;**51(2):**237-244.

19. Zhong VW, Kuang A, Danning RD, et al. A genome-wide association study of bitter and sweet beverage consumption [published correction appears in Hum Mol Genet. 2019 May 02;:]. *Hum Mol Genet*. 2019;**28(14):**2449-2457.

20. Dashti HS, Daghlas I, Lane JM, et al. Genetic determinants of daytime napping and effects on cardiometabolic health. *Nat Commun*. 2021;**12(1):**900.

21. Dashti HS, Jones SE, Wood AR, et al. Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates. *Nat Commun*. 2019;**10(1):**1100.

22. Klimentidis YC, Raichlen DA, Bea J, et al. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. *Int J Obes (Lond)*. 2018;**42(6):**1161-1176.

23. Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet*. 2018;**27(20):**3641-3649.

24. Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015;**518(7538):**187-196.

449 25. Bradfield JP, Taal HR, Timpson NJ, et al. A genome-wide association meta-
450 analysis identifies new childhood obesity loci. *Nat Genet*. 2012;**44(5):**526-531.
451 26. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to
452 single-variant resolution using high-density imputation and islet-specific epigenome
453 maps. *Nat Genet*. 2018;**50(11):**1505-1513.
454 27. Klarin D, Damrauer SM, Cho K, et al. Genetics of blood lipids among ~300,000
455 multi-ethnic participants of the Million Veteran Program. *Nat Genet*.
456 2018;**50(11):**1514-1523.
457 28. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1
458 million people identifies 535 new loci associated with blood pressure traits [published
459 correction appears in Nat Genet. 2018 Dec;50(12):1755]. *Nat Genet*.
460 2018;**50(10):**1412-1425.
461 29. Han X, Ong JS, An J, Hewitt AW, Gharahkhani P, MacGregor S. Using Mendelian
462 randomization to evaluate the causal relationship between serum C-reactive protein
463 levels and age-related macular degeneration. *Eur J Epidemiol*. 2020;**35(2):**139-146.
464 30. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring
465 population-specific haplotype structure and linking correlated alleles of possible
466 functional variants. *Bioinformatics.* 2015;**31(21):**3555-7.
467 31. McCartney DL, Min JL, Richmond RC, Lu AT, Sobczyk MK, Davies G, et al.
468 Genome-wide association studies identify 137 genetic loci for DNA methylation
469 biomarkers of aging. *Genome Biol*. 2021;**22(1):**194.
470 32. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian

471 randomization: using genes as instruments for making causal inferences in
472 epidemiology. *Stat Med*. 2008;**27(8):**1133-1163.
473 33. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
474 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
475 Estimator. *Genet Epidemiol*. 2016;**40(4):**304-314.
476 34. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for
477 Robust Causal Inference from Mendelian Randomization Analyses with Multiple
478 Genetic Variants. *Epidemiology (Cambridge, Mass)*. 2017;**28(1):**30-42.
479 35. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
480 pleiotropy in causal relationships inferred from Mendelian randomization between
481 complex traits and diseases. *Nat Genet.* 2018;**50(5):**693-8.
482 36. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A
483 framework for the investigation of pleiotropy in two-sample summary data Mendelian
484 randomization. *Stat Med.* 2017;**36(11):**1783-802.
485 37. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of
486 pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol*.
487 2015;**181(4):**251-260.
488 38. Figgins E, Pieruccini-Faria F, Speechley M, Montero-Odasso M. Potentially
489 modifiable risk factors for slow gait in community-dwelling older adults: A systematic
490 review. *Ageing Res Rev*. 2021;**66:**101253.
491 39. Bountziouka V, Musicha C, Allara E, et al. Modifiable traits, healthy behaviours,
492 and leukocyte telomere length: a population-based study in UK Biobank. *Lancet*

Healthy Longev. 2022;**3(5):**e321-e331.

40. Marioni RE, Harris SE, Shah S, et al. The epigenetic clock and telomere length are independently associated with chronological age and mortality [published correction appears in Int J Epidemiol. 2018 Feb 1;47(1):356]. *Int J Epidemiol*. 2018;**45(2):**424-432.

41. Brønnum-Hansen H, Juel K. Abstention from smoking extends life and compresses morbidity: a population based study of health expectancy among smokers and never smokers in Denmark. *Tob Control*. 2001;**10(3):**273-278.

42. Beach SR, Dogan MV, Lei MK, et al. Methylomic Aging as a Window onto the Influence of Lifestyle: Tobacco and Alcohol Use Alter the Rate of Biological Aging. *J Am Geriatr Soc*. 2015;**63(12):**2519-2525.

43. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [published correction appears in Lancet Psychiatry. 2019 Jan;6(1):e2]. *Lancet Psychiatry*. 2018;**5(12):**987-1012.

44. Loftfield E, Cornelis MC, Caporaso N, Yu K, Sinha R, Freedman N. Association of Coffee Drinking With Mortality by Genetic Variation in Caffeine Metabolism: Findings From the UK Biobank. *JAMA Intern Med*. 2018;**178(8):**1086-1097.

45. Wang C, Bangdiwala SI, Rangarajan S, et al. Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. *Eur Heart J*. 2019;**40(20):**1620-1629.

515 46. Gielen M, Hageman GJ, Antoniou EE, et al. Body mass index is negatively
516 associated with telomere length: a collaborative cross-sectional meta-analysis of 87
517 observational studies. *Am J Clin Nutr.* 2018;**108(3)**:453-475.

Table 1. Data sources of IVs for the 18 modifiable factors used in the MR study

Modifiable factor	PMID/ GWAS ID	Sample size	Ancestry	No. of SNPs[a]	Unit	P threshold[b]
Socioeconomic factor						
Educational attainment[17]	30038396	1131881	European	751	1-SD increase in years of schooling	$P < 5\times10^{-8}$
Lifestyle behavior						
Smoking initiation[18]	30643251	557337 cases and 674754 controls	European	299	log-odds (ever smoked regularly compared to never smoked)	$P < 5\times10^{-8}$
Alcohol intake[18]	30643251	941280	European	80	1-SD increase in log-transformed alcoholic drinks/week	$P < 5\times10^{-8}$
Coffee consumption[19]	31046077	375833	European	12	1% change	$P < 5\times10^{-8}$
Sleep						
Daytime napping[20]	33568662	452633	European	115	1 unit increase in napping category (responses “never, sometimes or usually napping” were treated as continuous variable)	$P < 5\times10^{-8}$
Sleep duration[21]	30846698	446118	European	77	1 hour/day	$P < 5\times10^{-8}$
MVPA[22]	29899525	377234	European	6	1-SD increase in MET-minutes/week of MVPA	$P < 5\times10^{-9}$
Cardiometabolic trait						
Adiposity						
BMI[23]	30124842	681275	European	941	1-SD increase in body mass index	$P < 5\times10^{-8}$

Waist circumference[24]	25673412	224459	European	44	1-SD increase in waist circumference	P <5×10^{-8}
BF%	ukb-b-8909	454633	European	641	1-SD increase in body fat percentage	P <5×10^{-8}
Childhood obesity[25]	22484627	5530 cases and 8318 controls	European	5	log-odds	P <5×10^{-8}
Type 2 diabetes[26]	30297969	71124 cases and 824006 controls	European	232	log-odds	P <5×10^{-8}
Lipids[27]						
LDL cholesterol	30275531	> 600000	mix	145	1-SD increase in LDL cholesterol	P <5×10^{-8}
HDL cholesterol	30275531	> 600000	mix	222	1-SD increase in HDL cholesterol	P <5×10^{-8}
Triglycerides	30275531	> 600000	mix	172	1-SD increase in triglycerides	P <5×10^{-8}
Blood pressure[28]						
SBP	30224653	>1 million	European	222	1 mmHg	P <5×10^{-8}
DBP	30224653	>1 million	European	264	1 mmHg	P <5×10^{-8}
CRP[29]	31900758	418642	European	299	1-SD increase in serum CRP levels	P <5×10^{-8}

[a]SNPs used in the present MR analysis.

[b]P threshold represents genome-wide significance threshold of genetic instruments.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; GWAS=genome-wide association study; HDL=high-density lipoprotein; IVs=instrumental variables; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism.

Table 2. MR results of the associations between 18 modifiable factors and GrimAgeAccel

		Main analysis			Sensitivity analyses									
		IVW			Weighted median			MR-Egger			MR-PRESSO			
Modifiable factor	**No. of SNP**	**β (SE)**	**P value**	**q value**	**β (SE)**	**P value**	**q value**	**β (SE)**	**P value**	**q value**	**No. of outlier**	**β (SE)**	**P value**	**q value**
Socioeconomic factor														
Educational attainment	751	**-1.143 (0.121)**	**3.31E-21**	2.98E-20	**-1.129 (0.172)**	**5.47E-11**	4.92E-10	-0.829 (0.452)	0.067	0.277	4	**-1.116 (0.116)**	**6.54E-21**	5.89E-20
Lifestyle behavior														
Smoking initiation	299	**1.299 (0.107)**	**4.90E-34**	8.82E-33	**1.257 (0.157)**	**1.42E-15**	2.56E-14	**1.321 (0.446)**	**0.003**	0.027	0	**1.276 (0.103)**	**7.63E-29**	1.37E-27
Alcohol intake	80	**0.899 (0.361)**	**0.013**	0.026	0.380 (0.567)	0.502	0.602	0.481 (0.738)	0.516	0.771	0	**0.967 (0.357)**	**0.008**	0.018
Coffee consumption	12	0.003 (0.005)	0.589	0.624	-0.003 (0.006)	0.615	0.692	-0.008 (0.010)	0.464	0.771	0	0.003 (0.005)	0.600	0.635
Sleep														
Daytime napping	115	**0.805 (0.355)**	**0.023**	0.038	0.524 (0.514)	0.308	0.449	0.411 (1.235)	0.740	0.833	0	**0.813 (0.346)**	**0.020**	0.033
Sleep duration	77	-0.301 (0.266)	0.257	0.356	-0.403 (0.400)	0.313	0.449	-0.077 (1.017)	0.940	0.940	0	-0.275 (0.261)	0.294	0.378
MVPA	6	-0.186 (0.903)	0.837	0.837	-0.036 (1.198)	0.976	0.976	-9.279 (5.557)	0.170	0.510	0	-0.186 (0.763)	0.817	0.817
Cardiometabolic trait														
Adiposity														
BMI	941	**0.592 (0.079)**	**9.16E-14**	5.50E-13	**0.490 (0.124)**	**7.92E-05**	3.56E-04	**0.790 (0.231)**	**0.001**	0.018	2	**0.595 (0.078)**	**6.30E-14**	3.78E-13
Waist circumference	44	**0.815 (0.184)**	**9.26E-06**	2.78E-05	**0.776 (0.272)**	**0.004**	0.014	0.913 (0.504)	0.077	0.277	0	**0.815 (0.184)**	**6.31E-05**	1.89E-04
BF%	641	**0.748 (0.120)**	**4.12E-10**	1.85E-09	**0.740 (0.182)**	**4.87E-05**	2.92E-04	**0.843 (0.400)**	**0.036**	0.216	3	**0.796 (0.115)**	**1.19E-11**	5.36E-11
Childhood obesity	5	**0.200 (0.075)**	**0.007**	0.016	0.142 (0.098)	0.146	0.292	0.789 (0.554)	0.249	0.560	0	**0.204 (0.057)**	**0.016**	0.029
Type 2 diabetes	232	**0.095 (0.041)**	**0.020**	0.036	0.084 (0.071)	0.236	0.425	0.043 (0.092)	0.644	0.773	0	**0.100 (0.040)**	**0.013**	0.026
Lipids														
LDL cholesterol	145	-0.094 (0.096)	0.327	0.392	-0.064 (0.163)	0.695	0.736	0.016 (0.142)	0.908	0.940	1	-0.069 (0.094)	0.463	0.542
HDL cholesterol	223	-0.181 (0.095)	0.056	0.084	-0.267 (0.138)	0.053	0.136	-0.078 (0.162)	0.632	0.773	2	-0.175 (0.090)	0.054	0.081
Triglycerides	173	**0.249 (0.091)**	**0.006**	0.015	0.239 (0.144)	0.096	0.216	0.152 (0.152)	0.319	0.638	0	**0.254 (0.091)**	**0.006**	0.015
Blood pressure														
SBP	222	0.013 (0.012)	0.279	0.359	0.015 (0.018)	0.421	0.541	0.029 (0.049)	0.557	0.771	0	0.013 (0.012)	0.282	0.378
DBP	264	0.011 (0.019)	0.565	0.624	0.027 (0.027)	0.324	0.449	0.083 (0.066)	0.213	0.548	0	0.013 (0.018)	0.482	0.542
CRP	299	**0.345 (0.073)**	**2.31E-06**	8.32E-06	**0.245 (0.107)**	**0.022**	0.066	0.060 (0.100)	0.553	0.771	1	**0.348 (0.071)**	**1.64E-06**	5.90E-06

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock. The q value represents the false discovery rate (FDR)-adjusted *P* value. β represents the associations with GrimAgeAccel of respectively: 1-SD increase in years of educational attainment; Ever smoked regularly compared to never smoked; 1-SD increase in log-transformed alcoholic drinks per week; 1%-change in coffee consumption; 1-unit increase in napping category (never, sometimes, usually); 1-hour/day increase in sleep duration; 1-SD increase in MET-minutes/week of MVPA; 1-SD increase in BMI; 1-SD increase in waist circumference; 1-SD increase in BF%; 1-unit increase in log-transformed odds of childhood obesity; 1-unit increase in log-transformed odds of type 2 diabetes; 1-SD increase in LDL cholesterol; 1-SD increase in HDL cholesterol; 1-SD increase in triglycerides; 1-mmHg increase in SBP; 1-mmHg increase in DBP; 1-SD increase in serum CRP levels.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=Inverse variance weighted; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; MR-PRESSO=Mendelian randomization pleiotropy residual sum and outlier; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism.

Table 3. MR results of the associations between 18 modifiable factors and PhenoAgeAccel

		Main analysis			Sensitivity analyses									
		IVW			Weighted median			MR-Egger			MR-PRESSO			
Modifiable factor	**No. of SNP**	**β (SE)**	**P value**	**q value**	**β (SE)**	**P value**	**q value**	**β (SE)**	**P value**	**q value**	**No. of outlier**	**β (SE)**	**P value**	**q value**
Socioeconomic factor														
Educational attainment	751	**-0.718 (0.151)**	**1.83E-06**	1.65E-05	**-0.633 (0.225)**	**0.005**	0.030	-0.361 (0.565)	0.523	0.930	3	**-0.689 (0.145)**	**2.52E-06**	2.27E-05
Lifestyle behavior														
Smoking initiation	299	**0.519 (0.142)**	**2.43E-04**	0.001	**0.404 (0.205)**	**0.049**	0.221	**1.222 (0.589)**	**0.039**	0.240	1	**0.545 (0.135)**	**7.20E-05**	3.24E-04
Alcohol intake	80	0.669 (0.441)	0.130	0.213	1.134 (0.656)	0.084	0.252	1.693 (0.923)	0.070	0.252	0	0.737 (0.432)	0.092	0.151
Coffee consumption	12	0.004 (0.008)	0.600	0.735	0.002 (0.007)	0.773	0.991	-0.003 (0.015)	0.861	0.930	0	0.004 (0.008)	0.610	0.705
Sleep														
Daytime napping	115	0.115 (0.500)	0.818	0.818	0.014 (0.665)	0.984	0.991	0.152 (1.742)	0.931	0.931	0	0.083 (0.488)	0.866	0.866
Sleep duration	77	-0.472 (0.357)	0.187	0.281	-0.526 (0.462)	0.255	0.417	**2.771 (1.324)**	**0.040**	0.240	0	-0.319 (0.357)	0.375	0.519
MVPA	6	0.368 (1.138)	0.747	0.791	0.262 (1.347)	0.846	0.991	-2.565 (6.947)	0.731	0.930	0	0.368 (0.649)	0.596	0.705
Cardiometabolic trait														
Adiposity														
BMI	941	**0.586 (0.102)**	**1.08E-08**	1.94E-07	**0.680 (0.170)**	**6.33E-05**	0.001	0.510 (0.298)	0.087	0.261	4	**0.605 (0.099)**	**1.53E-09**	2.75E-08
Waist circumference	44	**0.850 (0.269)**	**0.002**	0.006	0.632 (0.339)	0.062	0.223	0.739 (0.740)	0.324	0.704	1	**0.771 (0.249)**	**0.003**	0.009
BF%	641	**0.711 (0.152)**	**2.88E-06**	1.73E-05	**0.734 (0.227)**	**0.001**	0.009	**1.666 (0.509)**	**0.001**	0.018	4	**0.664 (0.145)**	**5.75E-06**	3.45E-05
Childhood obesity	5	**0.229 (0.095)**	**0.016**	0.036	0.154 (0.123)	0.211	0.380	0.140 (0.724)	0.859	0.930	0	**0.223 (0.071)**	**0.025**	0.050
Type 2 diabetes	232	**0.125 (0.051)**	**0.014**	0.036	0.102 (0.080)	0.205	0.380	0.056 (0.116)	0.628	0.930	0	**0.120 (0.049)**	**0.016**	0.036
Lipids														
LDL cholesterol	145	0.055 (0.123)	0.653	0.735	-0.002 (0.174)	0.991	0.991	0.169 (0.181)	0.352	0.704	1	0.059 (0.123)	0.633	0.705
HDL cholesterol	223	-0.127 (0.109)	0.243	0.336	0.068 (0.166)	0.684	0.947	0.103 (0.187)	0.583	0.930	0	-0.121 (0.109)	0.267	0.401
Triglycerides	173	-0.058 (0.121)	0.635	0.735	0.009 (0.196)	0.964	0.991	-0.202 (0.203)	0.320	0.704	0	-0.052 (0.121)	0.666	0.705
Blood pressure														
SBP	222	0.032 (0.016)	0.053	0.095	0.033 (0.023)	0.149	0.338	-0.013 (0.065)	0.840	0.930	1	**0.038 (0.016)**	**0.015**	0.036
DBP	264	**0.049 (0.024)**	**0.037**	0.074	0.048 (0.034)	0.150	0.338	0.161 (0.084)	0.055	0.248	0	0.042 (0.023)	0.069	0.124
CRP	298	**0.349 (0.095)**	**2.49E-04**	0.001	0.061 (0.150)	0.684	0.947	0.020 (0.132)	0.878	0.930	1	**0.362 (0.093)**	**1.16E-04**	4.18E-04

PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock; The q value represents the false discovery rate (FDR)-adjusted *P* value. β represents the associations with PhenoAgeAccel of respectively: 1-SD increase in years of educational attainment; Ever smoked regularly compared to never smoked; 1-SD increase in log-transformed alcoholic drinks per week; 1%-change in coffee consumption; 1-unit increase in napping category (never, sometimes, usually); 1-hour/day increase in sleep duration; 1-SD increase in MET-minutes/week of MVPA; 1-SD increase in BMI; 1-SD increase in waist circumference; 1-SD increase in BF%; 1-unit increase in log-transformed odds of childhood obesity; 1-unit increase in log-transformed odds of type 2 diabetes; 1-SD increase in LDL cholesterol; 1-SD increase in HDL cholesterol; 1-SD increase in triglycerides; 1-mmHg increase in SBP; 1-mmHg increase in DBP; 1-SD increase in serum CRP levels.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=Inverse variance weighted; LDL=low-density lipoprotein; MVPA=moderate-to vigorous physical activity; MR=Mendelian randomization; MR-PRESSO=Mendelian randomization pleiotropy residual sum and outlier; No=number; SBP=systolic blood pressure; SD=standard deviation; SNP=single nucleotide polymorphism

Figure 1. Study design and assumptions of the MR analysis

Assumption 1 indicates that the genetic variants proposed as instrumental variables should be robustly associated with the exposures; assumption 2 indicates that the used instrumental variables should not be associated with potential confounders of the relationship between exposures and outcomes; and assumption 3 indicates that the selected instrumental variables should influence the outcomes only through the exposures, not via alternative pathways.

Abbreviations: GrimAgeAccel=epigenetic-age acceleration obtained using the GrimAge clock; HDL=high-density lipoprotein; LDL=low-density lipoprotein; MR=mendelian randomization; PhenoAgeAccel=epigenetic-age acceleration obtained using the PhenoAge clock; PRESSO=pleiotropy residual sum and outlier.



Figure 2. Overview of the findings on associations between 18 modifiable factors and GrimAgeAccel

The IVW method was used for the main analysis. Sensitivity analyses included the MR-PRESSO, the MR-WM, and the MR-Egger methods. All results described here can be found in Table 2.

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock. β represents the association of each modifiable factor on GrimAgeAccel. Red box indicates a strong association with p value <0.05 and FDR q value <0.05. Blue box indicates a suggestive association with p value <0.05 and FDR q value ≥0.05. Grey box indicates null association with p value ≥0.05.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=inverse-variance weighted; LDL=low-density lipoprotein; MR=mendelian randomization; MVPA=moderate to vigorous physical activity; PRESSO=pleiotropy residual sum and outlier; SBP=systolic blood pressure; SD=standard deviation; WM=weighted median.



Figure 3. Overview of the findings on associations between 18 modifiable factors and PhenoAgeAccel

The IVW method was used for the main analysis. Sensitivity analyses included the MR-PRESSO, the MR-WM, and the MR-Egger methods. All results described here can be found in Table 3.

PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock; β represents the associations of each modifiable factor on PhenoAgeAccel. Red box indicates a strong association with p value <0.05 and FDR q value <0.05. Blue box indicates a suggestive association with p value <0.05 and FDR q value ≥0.05. Grey box indicates null association with p value ≥0.05.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CRP=C-reactive protein; DBP=diastolic blood pressure; HDL=high-density lipoprotein; IVW=inverse-variance weighted; LDL=low-density lipoprotein; MR=mendelian randomization; MVPA=moderate to vigorous physical activity; PRESSO=pleiotropy residual sum and outlier; SBP=systolic blood pressure; SD=standard deviation; WM=weighted median.



Figure 4. Univariable and multivariable MR assessing the effects of the strongest protective factor and risk factor on GrimAgeAccel and PhenoAgeAccel

Causal estimates are β (95% CI) in years.

GrimAgeAccel represents epigenetic-age acceleration obtained using the GrimAge clock; PhenoAgeAccel represents epigenetic-age acceleration obtained using the PhenoAge clock.

Abbreviations: BF%=body fat percentage; BMI=body mass index; CI=confidence intervals; MR=mendelian randomization.